Picankibart for palmoplantar pustulosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers at Xijing Hospital will enroll 60 adults with clinically or histologically confirmed palmoplantar pustulosis in a prospective, single-arm, open-label protocol to receive picankibart. Eligible participants must have failed or been intolerant to at least one conventional systemic therapy, and those with active hepatitis B, hepatitis C, tuberculosis, or pregnancy are excluded. Participants will receive picankibart according to the study protocol with scheduled dermatology follow-up visits to monitor skin response and safety. As a single-center, uncontrolled trial, the study is intended to provide safety data and preliminary signals of effectiveness rather than definitive comparative efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18-65 years, regardless of gender. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology.

Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.

Considered suitable for treatment with picankibart as assessed by the clinician.

Voluntarily participate in the study and provide written informed consent.

Exclusion Criteria:

* Patients with active hepatitis B, hepatitis C, or tuberculosis. Pregnant patients or those planning pregnancy within 6 months. Subjects unable to comply with follow-up as required by the study protocol. Other conditions deemed unsuitable for this study.

Where it's running

• Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Shuai Shao
• Email: 2269744794@qq.com
• Phone: 8619249282690

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bimekizumab for palmoplantar pustulosis (PPP)

  This trial tests whether bimekizumab helps adults with palmoplantar pustulosis and is safe compared with a placebo.

  Recruiting at 91 sites Phase 3 UCB Pharma · Birmingham, Alabama and 90 other locations · NCT07219420

• 16-week delgocitinib cream treatment for adults with palmoplantar pustulosis

  This 16-week test will see if applying delgocitinib cream twice daily helps adults with mild to severe palmoplantar pustulosis compared with a non-active cream.

  Recruiting at 38 sites Phase 2 LEO Pharma · Fountain Valley, California and 39 other locations · NCT07013201

• Collecting samples from people with skin conditions and healthy volunteers

  This study is collecting samples from people with different skin conditions and healthy volunteers to see how their biology differs and learn more about these conditions.

  Recruiting Innovaderm Research Inc. · Montreal, Quebec · NCT05994976

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.